Greg Winter

Sir Gregory " Greg" Paul Winter, CBE (born 14 April 1951) is a British molecular biologist and pioneer of monoclonal antibodies. He developed around 1986 techniques ( phage display ) further (not about and based on the mouse ) allowed for the first time such antibodies on a purely human basis.

Winter was co-director of the Division of Protein and Nucleic Acid Chemistry and Biotechnology at the Laboratory of Molecular Biology in Cambridge and previously deputy director at the Centre for Protein Engineering of the Medical Research Council. In 1989, he was founder of Cambridge Antibody Technology (from 2006 sold to AstraZeneca), which the blockbuster drug adalimumab ( HUMIRA ) developed (later marketed by Abbott Laboratories and developed ). It was the first antibody drug ( an inhibitor of the tumor necrosis factor ) on a purely human basis.

Winter founded other companies, so sold Domantis 2006 GlaxoSmithKline, and 2009 Bicycle Therapeutics.

In 1990 he was awarded the Emil von Behring Prize, 1995 together with Mark M. Davis and Tak W. Mak the King Faisal Award and the 1999 William B. Coley Award from the Cancer Research Institute and the 2002 Gabbay Award. In 2004 he was knighted. In 2012 he was awarded the Prince of Asturias Award for Technical and Scientific Research and the Canada Gairdner International 2013 Award. He is a Fellow of the Royal Society (1990). Since 1991 he is a Fellow and from October 2, 2012 Master of Trinity College, Cambridge.